"One of the leading Cancer hospitals in India with a 275-bed capacity. Successfully treated more than 70000 patients since our inception in 2007 and adding on.Successfully treated 13000+ patients by Radiotherapy, 40000+ surgeries. More than 450 patients are showing their trust in the hospital daily.1st NABH Accredited cancer centre in Central India.1st Hospital in the region to launch an ultra modern dedicated Department of Nuclear Medicine with PET-CT Scan & Gamma Camera.1st Hospital in the region to launch the latest advancement in Radiotherapy with TomoTherapy-H, Linear Accelerator & Versa HD Radiotherapy Unit 1st in the region to start Bone Marrow Transplant & Hemato Oncology department with 4 procedure rooms. Started Robotic Surgery."

During the past decade, HCG Manavata Cancer Centre conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 9 clinical trials were completed, i.e. on average, 32.1% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 4 clinical trials were completed. i.e. 22.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "HCG Manavata Cancer Centre" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored, "Piramal Enterprises Limited" with 3 trials sponsored and "Bayer" with 3 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "HCG Manavata Cancer Centre" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "BeiGene, Ltd." with 1 trials as a collaborator, "Cephalon" with 1 trials as a collaborator, "Lambda Therapeutic Research Ltd." with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "HCG Manavata Cancer Centre" are "Breast Neoplasms" (4 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Breast Cancer" (3 trials), "Neoplasm Metastasis" (2 trials) and "Adenocarcinoma" (1 trials). Many other conditions were trialed in "HCG Manavata Cancer Centre" in a lesser frequency.

Most popular intervention types in "HCG Manavata Cancer Centre" are "Drug" (37 trials), "Biological" (3 trials), "Diagnostic Test" (1 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Abemaciclib" (3 trials), "Amivantamab" (3 trials), "Carboplatin" (3 trials) and "Lazertinib" (3 trials). Other intervention names were less common.

The vast majority of trials in "HCG Manavata Cancer Centre" are 32 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "HCG Manavata Cancer Centre". undefined are not yet recruiting, 15 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in HCG Manavata Cancer Centre, 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in HCG Manavata Cancer Centre, 7 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".